릴게임 체리마스터 59.rnd245.top 바로가기 온라인 슬롯 머신 게임, 잭팟 슬롯

바다이야기pc버전다운모바일황금성황금성 게임랜드씨엔조이 릴게임

온라인야마토게임 22.rnd245.top 신천지게임하는방법

야마토3다운로드게임사이트 75.rnd245.top 무료슬롯사이트

바다이야기 게임 방법 17.rnd245.top 바다이야기릴게임사이트추천및안내

바다이야기 예시 61.rnd245.top 슬롯사이트 순위

pc게임 84.rnd245.top 온라인 야마토 게임

바다이야기무료체험 62.rnd245.top 야마토다운

황금성검증 68.rnd245.top 야마토릴게임

슬롯 추천 디시 8.rnd245.top 릴게임뜻

블랙잭하는법 22.rnd245.top 바다이야기 프로그램

온라인룰렛 80.rnd245.top 럭키세븐

바로가기 go !! 바로가기 go !!

오션바다이야기게임 오션파라다이스 온라인 바다이야기 무료게임 카지노릴게임 오락실릴게임 슬롯 머신 제작 신천지게임하는곳 바다이야기게임공략방법 바다이야기 예시 종료 바다이야기게임공략방법 골드몽릴게임 골드몽 온라인야마토2 모바일신천지 야마토2게임동영상 오리 지날 바다 야마토2다운로드 야마토3게임다운로드후기 실시간파워볼 릴게임 신천지 무료충전 바다이야기 양귀비게임 바다이야기동영상 황금성배당 야마토노하우 온라인슬롯 전략 오리지날야마토 오션파라다이스예시 황금성배당 온라인배경 바다이야기 조작 손오공 야마토5게임공략법 강원랜드 슬롯머신 규칙 야마토다운로드 야마토5다운로드게임사이트 바다이야기 부활 바둑이라이브 파칭코하는법 슬롯 머신 html 무료게임다운로드 릴게임팡게임 무료 슬롯 메타 야마토 프라그마틱 슬롯 사이트 슬롯 추천 디시 온라인슬롯머신 백경게임 하는곳주소 모바일오션 파라 다이스7 바다이야기 게임 슬롯 추천 디시 릴게임5만릴게임사이다 신천지 10원야마토게임 백경예시 신천지게임사이트 야마토게임 방법 온라인 슬롯 머신 게임 무료인터넷게임 백경 일본야마토게임 야마토 빠칭코 릴114 호게임 온라인 슬롯 머신 게임 손오공다운로드 오리지날게임 바다 이야기 다운 카카오바다이야기 야마토 게임 오락실 빠찡코 하는 방법 게임몰릴게임 오션파라다이스예시 야마토3 해외축구일정 게임바둑이추천 바다이야기하는곳 황금성 릴게임 바다이야기고래출현 야마토2다운로드 야마토게임장주소 바다이야기 환전 가능 올벳매거진 온라인릴게임먹튀검증 오션파라다이스하는방법 슬롯 무료스핀 바다이야기 모바일 Pg 소프트 무료 체험 야마토연타 바다 슬롯 먹튀 강원랜드슬롯머신 릴게임판매 슬롯 머신 제작 일본 야마토 게임 오리지날 야마토 황금성게임공략방법 모바일 바다이야기 10원바다이야기 바다신2다운로드 온라인삼국지 알라딘오락실 바다이야기주소 신천지릴게임장주소 온라인오션게임 릴게임안전사이트 오션슬롯 먹튀 빠칭코 슬롯머신 바다이야기 게임 오리지널바다이야기 바다이야기 릴게임 사이트 추천 및 안내 무료 바다이야기 한게임바둑이게임 중고게임기 매매 일본경륜 온라인파칭코 슬롯게임 하는법 무료인터넷게임 무료충전 바다이야기 모바일 바다이야기 바다이야기 하는 법 릴야마토 일본 파칭코 프라그마틱 슬롯 하는법 일본경륜 야마토 릴게임 This article was released as Pharm Edaily Premium Content on September 24, 2025, at 7:16 AM.


[Shin-Min Joon, Edaily Reporter] On September 23 in the South Korean pharmaceutical and biotechnology stock market, remarkable stock surges were seen in Celltrion, Protina, and Viol. Celltrion’s share price rose on expectations that tariff risk would be alleviated by acquir 신용불량자 조회 ing a US biologics manufacturing facility from global pharma company Eli Lilly.
Protina’s stock jumped sharply after securing a clinical specimen analysis service contract with a multinatio 학자금전환대출 nal company. Viol which is facing delisting procedures on KOSDAQ hit the daily upper price limit for three consecutive days driven by a dominance of buying amid decreased trading volume.

cd금리상승


◇Celltrion Acquires Eli Lilly’s Biologics Facility for 460 Billion Won

According to KG Zeroin’s MP Doctor (formerly MarketPoint), Celltr 상여금 400% ion’s stock closed at won 184,200 up 8.93% from the previous trading day. After falling the day before the share price rebounded buoyed by the announcement of a won 460 billion acquisition of Eli Lill 1년 정기예금 금리 y’s biologics manufacturing plant in Branchburg New Jersey, U.S. The transaction lifted investor expectations of reduced tariff risk.
The facility is a large scale campus on 45,000 pyung (149,000 m²), comprising four buildings: a production facility, a logistics warehouse, a technical support wing, and an operations building. Because Celltrion owns unused land of about 11,000 pyung (36,400 m²) on the site, it has room for expansion, which could allow the company to respond preemptively to rising market demand.
Though the headline purchase price is 460 billion won total investment including initial operating expenses and facility expansion is expected to reach won 1.4 trillion over the long term. Celltrion plans to finance it via borrowing and inject the capital into its U.S. subsidiary Celltrion USA, through a paid in capital increase.
In an online press briefing Celltrion Group Chairman Seo Jung jin said “If the U.S. demands tariffs, investing in the U.S. is the answer.”
He added “To deal with tariff issues, we’ve maintained inventory for two years.” He also said that before its domestic production facility is ready Celltrion will sell products made in the USA under contract manufacturing (CMO) agreements. Negotiations to acquire the New Jersey facility from Eli Lilly began about six months ago.
Though other companies vied for it Celltrion was designated as preferred bidder. The formal contract was finalized on September 20. Half of the production lines in the purchased facility will continue manufacturing Eli Lilly products under contract while the other half will be used for Celltrion’s own products. Full scale production including transfer of operations from Lilly validating Celltrion’s own products, and obtaining necessary re approvals is expected in the second half of next year.
The biotech industry views this move as resolving tariff related uncertainties for Celltrion. In addition to mitigating tariff risk industry observers anticipate that Celltrion’s earnings will improve thanks to expansion of its contract manufacturing business. New revenue from CMO contracts with Eli Lilly is expected. The company plans to increase capacity, targeting a facility size about 1.5 times larger than its Incheon Songdo Plant 2. Accordingly its operating margin is expected to gradually rise.
Chairman Seo also noted “The facility isn’t just manufacturing staff it includes R&D personnel and production technology teams making it a natural opportunity to relocate or integrate U.S. based laboratories.” This he said would strengthen a bilateral research system anchored in Songdo, Korea and New Jersey U.S.
◇Protina Secures Global Contract for Clinical Specimen Analysis Services
Protina’s stock closed at won 43,400 up 29.94% compared to the previous day hitting its daily upper bound. The surge followed the company’s securing of a contract worth about 1.2 billion won to supply clinical specimen analysis services to a multinational U.S. pharmaceutical firm. Established in 2015 as a KAIST faculty startup Protina is a big data protein company whose core competency is analyzing protein protein interactions (PPI).
Protina operates a single molecule protein interaction (SPID) platform called PPI Landscape used to quantify interactions among proteins across various sample types feeding into drug discovery.
By rapidly acquiring large datasets of antigen antibody interaction data the platform helps in developing biobetters or discovering new drug candidates. Understanding the composition of protein complexes and interaction networks more precisely boosts success probabilities in identifying disease targets, developing biomarkers and designing modulators.
Notably Protina has drawn attention through an investment by global investment bank JPMorgan. As of July 10 the Asia Pacific branch of JPMorgan Asset Management held a 2.89% stake. Protina has said that JPMorgan’s favorable evaluation of the business potential of its PPI Landscape platform, even before the stock listing, was a key reason for the investment.
A company official commented “The contract shows that our unique technology has been validated which seems to have positively influenced the stock price.”
◇Viol Approaches KOSDAQ Delisting, Stock Hits Three Day Upper Limit
Viol’s share price rose 29.90% from the previous day to won?27,150, marking its third consecutive day at the daily upper price limit. The surge is attributed to a diminished trading volume creating a situation where buying pressure dominates. Indeed, the trading volume dropped from 882,874 shares on September 21 to just 260,321 shares on this day.
Recently, Viol’s majority shareholder changed. In May VIG Partners acquired 56.9% of Viol’s management rights from DMS for 367.9 billion won. Through a tender offer from June 18 to July 7, VIG Partners increased its shareholding to around 85%, then continued purchasing remaining shares on the open market. To prepare for delisting, VIG Partners formed a special purpose company called Vienna Investment Vehicle in June. On July 9 it disclosed the possibility of a cash?settled comprehensive share exchange. This procedure would force purchase of minority shareholders’ shares in order to delist. Once shareholding exceeds 95%, Viol may directly apply for delisting with the Korea Exchange.
If the share purchase agreement between DMS and VIG Partners concludes successfully on September 29 VIG Partners’ ownership will rise to 96.57%. Delisting generally proceeds via board resolution followed by convening a shareholders’ meeting. If approved via a special resolution, the company applies for delisting with the Korea Exchange. After passing the exchange’s review a period of organized trading for remaining shares is set before final delisting occurs.
Viol a medical device company specializing in cosmetic skin beauty equipment, has consistently posted record revenues and operating profits. Last year it recorded sales of 58.2 billion won and operating profit of 36.1 billion won.
Its operating margin of 62% was among the highest in the industry. The company was first to develop a high frequency cosmetic device using microneedles as small as 300 micrometers (μm).
An official at Viol said “There is no particular new development the reduced trading volume has made the buying side more noticeable.”
신민준 (adonis@edaily.co.kr)